Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CALC 
CalciMedica, Inc. Common Stock (CALC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CALC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16.25
1 Year Target Price $16.25
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.19% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.41M USD | Price to earnings Ratio - | 1Y Target Price 16.25 |
Price to earnings Ratio - | 1Y Target Price 16.25 | ||
Volume (30-day avg) 4 | Beta 1.31 | 52 Weeks Range 1.42 - 5.65 | Updated Date 10/17/2025 |
52 Weeks Range 1.42 - 5.65 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.95% | Return on Equity (TTM) -209.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33158139 | Price to Sales(TTM) - |
Enterprise Value 33158139 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.26 | Shares Outstanding 13972177 | Shares Floating 5475137 |
Shares Outstanding 13972177 | Shares Floating 5475137 | ||
Percent Insiders 16.22 | Percent Institutions 58.81 |
Upturn AI SWOT
CalciMedica, Inc. Common Stock
Company Overview
History and Background
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for severe inflammatory and autoimmune diseases by targeting calcium release-activated calcium (CRAC) channels. Founded to address unmet needs in these areas, they've progressed through various development stages with their lead candidates.
Core Business Areas
- Drug Development: Focuses on the research and development of novel therapies that target CRAC channels to treat inflammatory and autoimmune diseases.
Leadership and Structure
Details on leadership structure can be found on CalciMedica's Investor Relations website. The structure typically includes a CEO, CFO, CSO, and a board of directors.
Top Products and Market Share
Key Offerings
- CRAC Channel Inhibitors: Their primary focus is on developing CRAC channel inhibitors. Their lead compound is Auxorau2122, a potent and selective Orai1 inhibitor. There is no definitive market share data yet, as the drug is still in clinical development. Competitors depend on the target indication and may include companies like Roche and Novartis, which have autoimmune therapies targeting different mechanisms.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and significant competition. The inflammatory and autoimmune disease market is large and growing, driven by an aging population and increased awareness of these conditions.
Positioning
CalciMedica is positioning itself as a leader in CRAC channel inhibition for inflammatory and autoimmune diseases. Their competitive advantage lies in the specificity and potency of their lead compound.
Total Addressable Market (TAM)
The TAM for inflammatory and autoimmune disease therapies is estimated to be in the billions of dollars. CalciMedica aims to capture a significant portion of this market with its novel CRAC channel inhibitors, targeting specific indications with high unmet need.
Upturn SWOT Analysis
Strengths
- Novel CRAC channel inhibitor technology
- Experienced management team
- Focus on high unmet medical needs
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Single lead product candidate (Auxorau2122)
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from existing and emerging therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Novartis (NOVN.SW)
- Bristol Myers Squibb (BMY)
Competitive Landscape
CalciMedica is competing with established pharmaceutical companies in the inflammatory and autoimmune disease market. Their advantage lies in their novel CRAC channel inhibitor technology, but they face challenges related to clinical trial success and funding.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to clinical development and regulatory milestones.
Future Projections: Future growth is dependent on successful clinical trials and potential commercialization of their drug candidates. Analyst estimates can be found on financial news websites.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Auxorau2122 in different indications.
Summary
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel therapies by targeting CRAC channels. They have a novel technology and are focused on high unmet needs, but are reliant on clinical trial successes. Their biggest need is to continue positive results in their clinical trials and they need to lookout for running out of capital before the clinical trials are completed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- CalciMedica's Investor Relations website
- SEC filings (10-K, 10-Q)
- Financial news websites
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CalciMedica, Inc. Common Stock
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2020-09-25 | CEO & Director Dr. A. Rachel Leheny Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://calcimedica.com |
Full time employees 15 | Website https://calcimedica.com | ||
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.